Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH

Abstract miRNAs are involved in the development of metabolic associated fatty liver disease (MAFLD) and nonalcoholic steatohepatitis (NASH). We aimed to evaluate modifications by prolonged-release pirfenidone (PR-PFD) on key hepatic miRNAs expression in a MAFLD/NASH model. First, male C57BL/6J mice...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rebeca Escutia-Gutiérrez, J. Samael Rodríguez-Sanabria, C. Alejandra Monraz-Méndez, Jesús García-Bañuelos, Arturo Santos-García, Ana Sandoval-Rodríguez, Juan Armendáriz-Borunda
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3d0a5ea6aa3f4130aece7fe0791813bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3d0a5ea6aa3f4130aece7fe0791813bc
record_format	dspace
spelling	oai:doaj.org-article:3d0a5ea6aa3f4130aece7fe0791813bc2021-12-02T18:24:53ZPirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH10.1038/s41598-021-91187-22045-2322https://doaj.org/article/3d0a5ea6aa3f4130aece7fe0791813bc2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91187-2https://doaj.org/toc/2045-2322Abstract miRNAs are involved in the development of metabolic associated fatty liver disease (MAFLD) and nonalcoholic steatohepatitis (NASH). We aimed to evaluate modifications by prolonged-release pirfenidone (PR-PFD) on key hepatic miRNAs expression in a MAFLD/NASH model. First, male C57BL/6J mice were randomly assigned into groups and fed with conventional diet (CVD) or high fat and carbohydrate diet (HFD) for 16 weeks. At the end of the eighth week, HFD mice were divided in two and only one half was treated with 300 mg/kg/day of PR-PFD mixed with food. Hepatic expression of miRNAs and target genes that participate in inflammation and lipid metabolism was determined by qRT-PCR and transcriptome by microarrays. Increased hepatic expression of miR-21a-5p, miR-34a-5p, miR-122-5p and miR-103-3p in MAFLD/NASH animals was reduced with PR-PFD. Transcriptome analysis showed that 52 genes involved in lipid and collagen biosynthesis and inflammatory response were downregulated in PR-PFD group. The expression of Il1b, Tnfa, Il6, Tgfb1, Col1a1, and Srebf1 were decreased in PR-PFD treated animals. MAFLD/NASH animals compared to CVD group showed modifications in gene metabolic pathways implicated in lipid metabolic process, inflammatory response and insulin resistance; PR-PFD reversed these modifications.Rebeca Escutia-GutiérrezJ. Samael Rodríguez-SanabriaC. Alejandra Monraz-MéndezJesús García-BañuelosArturo Santos-GarcíaAna Sandoval-RodríguezJuan Armendáriz-BorundaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Rebeca Escutia-Gutiérrez J. Samael Rodríguez-Sanabria C. Alejandra Monraz-Méndez Jesús García-Bañuelos Arturo Santos-García Ana Sandoval-Rodríguez Juan Armendáriz-Borunda Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
description	Abstract miRNAs are involved in the development of metabolic associated fatty liver disease (MAFLD) and nonalcoholic steatohepatitis (NASH). We aimed to evaluate modifications by prolonged-release pirfenidone (PR-PFD) on key hepatic miRNAs expression in a MAFLD/NASH model. First, male C57BL/6J mice were randomly assigned into groups and fed with conventional diet (CVD) or high fat and carbohydrate diet (HFD) for 16 weeks. At the end of the eighth week, HFD mice were divided in two and only one half was treated with 300 mg/kg/day of PR-PFD mixed with food. Hepatic expression of miRNAs and target genes that participate in inflammation and lipid metabolism was determined by qRT-PCR and transcriptome by microarrays. Increased hepatic expression of miR-21a-5p, miR-34a-5p, miR-122-5p and miR-103-3p in MAFLD/NASH animals was reduced with PR-PFD. Transcriptome analysis showed that 52 genes involved in lipid and collagen biosynthesis and inflammatory response were downregulated in PR-PFD group. The expression of Il1b, Tnfa, Il6, Tgfb1, Col1a1, and Srebf1 were decreased in PR-PFD treated animals. MAFLD/NASH animals compared to CVD group showed modifications in gene metabolic pathways implicated in lipid metabolic process, inflammatory response and insulin resistance; PR-PFD reversed these modifications.
format	article
author	Rebeca Escutia-Gutiérrez J. Samael Rodríguez-Sanabria C. Alejandra Monraz-Méndez Jesús García-Bañuelos Arturo Santos-García Ana Sandoval-Rodríguez Juan Armendáriz-Borunda
author_facet	Rebeca Escutia-Gutiérrez J. Samael Rodríguez-Sanabria C. Alejandra Monraz-Méndez Jesús García-Bañuelos Arturo Santos-García Ana Sandoval-Rodríguez Juan Armendáriz-Borunda
author_sort	Rebeca Escutia-Gutiérrez
title	Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
title_short	Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
title_full	Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
title_fullStr	Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
title_full_unstemmed	Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
title_sort	pirfenidone modifies hepatic mirnas expression in a model of mafld/nash
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/3d0a5ea6aa3f4130aece7fe0791813bc
work_keys_str_mv	AT rebecaescutiagutierrez pirfenidonemodifieshepaticmirnasexpressioninamodelofmafldnash AT jsamaelrodriguezsanabria pirfenidonemodifieshepaticmirnasexpressioninamodelofmafldnash AT calejandramonrazmendez pirfenidonemodifieshepaticmirnasexpressioninamodelofmafldnash AT jesusgarciabanuelos pirfenidonemodifieshepaticmirnasexpressioninamodelofmafldnash AT arturosantosgarcia pirfenidonemodifieshepaticmirnasexpressioninamodelofmafldnash AT anasandovalrodriguez pirfenidonemodifieshepaticmirnasexpressioninamodelofmafldnash AT juanarmendarizborunda pirfenidonemodifieshepaticmirnasexpressioninamodelofmafldnash
_version_	1718378089782706176

Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH

Ejemplares similares